Hugel, Inc.
145020.KQ - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.94T
Close$
$269209.02
38.5% upside
Current Fair Value
38.5% upsideUndervalued by 38.5% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.94 Trillion |
|---|---|
| Enterprise Value | $1.71 Trillion |
| Earnings per Share | $13061 |
| Beta | 0.5 |
| Outstanding Shares | 12,701,000 |
Return
| Return on Equity | 14.97% |
|---|---|
| Return on Assets | 13.25% |
| Return on Invested Capital | 16.40% |
Valuation & Multiples
| P/E Ratio | 12.97 |
|---|---|
| PEG | 68.36 |
| Price to Sales | 5.15 |
| Price to Book Ratio | 2.27 |
| Enterprise Value to Revenue | 3.57 |
| Enterprise Value to EBIT | 9.57 |
| Enterprise Value to Net Income | 10 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 4, 2026
EPS Estimate
$1161.11
Consensus analyst estimateRevenue Estimate
$103.92 B
Consensus analyst estimateNext Earnings Call
Expected Date
February 17, 2027
EPS Estimate
$2641.05
Consensus analyst estimateRevenue Estimate
$140.72 B
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Hugel, Inc.
629 employees
CEO: Carrie C. Strom
Hugel, Inc. is a biopharmaceutical firm headquartered in Chuncheon-si, South Korea, with a presence both domestically and internationally. The company specializes in the development and manufacturing of diverse medical solutions. A prima...